During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Naveen Pemmaraju, MD Anderson Cancer Center, Houston, US. We asked, Why does adding navitoclax to ruxolitinib induce responses in patients with relapsed/refractory myelofibrosis?